Endometrial inadequacy after treatment with human menopausal gonadotropin/human chorionic gonadotropin

E. Reshef, J. H. Segars, G. A. Hill, D. D. Pridham, M. A. Yussman, A. C. Wentz

Research output: Contribution to journalArticle

Abstract

The incidence of abnormal endometrial histology in patients undergoing human menopausal gonadotropin/human chorionic gonadotropin (hMG/hCG) treatment during cycles of in vitro fertilization (IVF) or gamete intrafallopian transfer has been reported to be 52% to 91%. The incidence of endometrial inadequacy, as judged by a single late luteal endometrial biopsy, has not been studied in hMG/hCG non-IVF cycles. In the current study, 30 patients (30 cycles) undergoing hMG/hCG treatment were evaluated by an endometrial biopsy. The incidence of endometrial inadequacy was found to be 27%. No preovulatory predictors for endometrial inadequacy could be identified. Therefore, luteal support for patients undergoing non-IVF hMG/hCG cycles should be considered.

Original languageEnglish (US)
Pages (from-to)1012-1016
Number of pages5
JournalFertility and sterility
Volume54
Issue number6
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Endometrial inadequacy after treatment with human menopausal gonadotropin/human chorionic gonadotropin'. Together they form a unique fingerprint.

Cite this